glucagon

all catalysts(0)

nothing on the calendar yet

News(10)

• 3 takeaways from a European obesity scientific meeting
  Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…
  biopharma_dive · 4h ago
• Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
  Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…
  biospace · 6h ago
• Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
  A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…
  fiercebiotech · 14h ago
• Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
  Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body we…
  fiercebiotech · 1d ago
• CDER director, expert discuss scientific, legal challenges to bringing generic GLP-1s to market
  Michael Davis, the director of the FDA's Center for Drug Evaluation and Research (CDER), stated that increasing the availability of generic versions of glucagon-like peptide-1 (GLP-1) medications i…
  raps · 3d ago
• Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
  Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more tha…
  biospace · 9d ago
• Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
  With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could supp…
  biospace · 9d ago
• Lilly cans early experimental obesity drug after ‘high bar’ not met
  Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
  fiercebiotech · 17d ago
• Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
  Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…
  biospace · 1mo ago
• Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
  Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the na…
  fiercebiotech · 1mo ago